神经皮肤黑变病并颅内黑色素瘤1例

2020-03-30 张晓杰 于谦 刘岩 中国临床神经外科杂志

男,16岁。因发现全身多发褐色至黑色斑块1年、间断性恶心呕吐伴癫痫发作半年于2017年6月8日首次入住我院。

1. 病例资料

男,16岁。因发现全身多发褐色至黑色斑块1年、间断性恶心呕吐伴癫痫发作半年于2017年6月8日首次入住我院。脑电图示多发癫痫样放电波。颅脑MRI检查显示,脑实质表面软脑膜弥漫性增厚、强化(图1A)。MRV示静脉窦血液回流欠佳(图1B、1C)。给予降颅内压、抗癫痫、营养神经、抗病毒等药物治疗。近半年内,上述症状反复发作6次,腰椎穿刺术取脑脊液病理学检查见黑色素瘤细胞及蛛网膜上皮细胞;脑脊液常规检查示白细胞(脑脊液)50×106/L;脑脊液生化检查示脑脊液乳酸脱氢酶63.31 U/L,微量蛋白3357.98mg/L。考虑为“颅内黑色素瘤”。

 1585526109760959.png

图1 A. 首次入院颅脑MRI检查,示脑实质表面软脑膜弥漫性增厚并强化,可符合炎性改变MRI表现;B、C. 首次入院MRV检查示左侧乙状窦、横窦、颈内动脉显影欠佳,窦汇处显影欠佳,下矢状窦未见显影;

2017年12月25日出现双眼视物不清,症状进行性加重;半个月后,双眼完全失明。颅脑MRI 示软脑膜弥漫性增厚并强化,较前进展,脑积水(图1D~F)。

 1585526129543196.png

图1 D. 距首次入院半年MRI复查示软脑膜弥漫性增厚并强化,较前进展,脑室系统扩张,考虑脑积水,脑室周围局部间质性脑水肿;E、F. 距首次入院半年MRV复查示左侧乙状窦、横窦、颈内静脉、右侧乙状窦、直窦、窦汇未见明确显影,右侧横窦、双侧大脑内静脉、大脑大静脉、上矢状窦纤细;

2018年1月11日行脑室-腹腔分流术,术中发现硬膜黑变。取硬脑膜、小部分脑组织病理活检示:(脑)脑组织轻度水肿,间质充血(硬脑膜)纤维结缔组织中查见少许增生的黑色素细胞;免疫组化示细胞角蛋白光谱(-);抗黑素瘤抗体(+);Ki-67(5%:+);Melan-A(-);S-100蛋白(+)。术后视力无改善。2018年2月10日意识变差、吞咽困难、饮水呛咳。颅脑CT示双侧硬膜下积液(图1G)。急诊行硬膜下钻孔引流术。术后复查颅脑CT示硬膜下积液改善明显(图1H)。住院期间病情进行性加重,最终因呼吸、循环功能衰竭死亡。

 1585526147645981.png

图1G. 距首次入院8个月CT 检查示脑室-腹腔分流术后改变,双侧硬膜下积液,其中以左侧显著;H. 硬膜下钻孔引流术后颅脑CT,示脑室-腹腔分流术后改变,左侧硬膜下积液消失

2. 讨论

神经皮肤黑变病是一种罕见的非家族遗传性神经皮肤综合征的一种,无明显性别差异,无家族史,具有散在发病等特点。其基本特征为先天性巨大或多发性皮肤色素痣伴中枢系统黑素细胞增生。诊断标准为:大片或多发的异常先天性色素痣;皮肤色素痣无恶变征象;除神经系统外,其他器官无原发性恶性黑素瘤。

由于黑素为顺磁性物质,MRI检查对黑素较为敏感,表现为短T1、短T2信号。神经皮肤黑变病脑脊液检查可以见脑脊液压力增高,蛋白含量增加,胞质内含有黑素颗粒;脑膜病理活检主要表现为增生的黑色素细胞。神经皮肤黑变病好发于儿童及青年,皮损表现为位于背部中轴的巨大型黑色素细胞痣,伴有卫星灶,主要分布在头部、肩部及四肢等,上覆毛发。中枢神经系统病变可表现为颅内压增高、癫痫样发作、神经症状等。

目前,神经皮肤黑变病无有效的治疗方法,预后差,转变为恶性黑素瘤的概率在6%~60%。一般在1~2岁前发病者,预后差,大约50%的患儿在1岁以内死于脑膜、脑脊髓的黑素细胞浸润,个别病例可存活至20岁以上。本文病例为16岁青年,半年前出现神经系统症状,短期内病情进行性加重,最终因脑膜黑素细胞浸润,导致呼吸、循环功能衰竭而死亡。

原始出处:

张晓杰,于谦,刘岩,张舒婉,常海春,李涛,辛国强.神经皮肤黑变病并颅内黑色素瘤1例[J].中国临床神经外科杂志,2019(03):191.

评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2079008, encodeId=c59020e9008f9, content=<a href='/topic/show?id=6035e44096e' target=_blank style='color:#2F92EE;'>#神经皮肤黑变病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74409, encryptionId=6035e44096e, topicName=神经皮肤黑变病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Fri Apr 24 06:30:13 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680662, encodeId=8c6e168066217, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Dec 31 07:30:13 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381240, encodeId=048138124057, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=090d49833, createdName=LaserDermatol, createdTime=Thu Apr 02 01:04:25 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559002, encodeId=7c62155900241, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Apr 01 04:30:13 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565011, encodeId=927e15650115c, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Apr 01 04:30:13 CST 2020, time=2020-04-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2079008, encodeId=c59020e9008f9, content=<a href='/topic/show?id=6035e44096e' target=_blank style='color:#2F92EE;'>#神经皮肤黑变病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74409, encryptionId=6035e44096e, topicName=神经皮肤黑变病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Fri Apr 24 06:30:13 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680662, encodeId=8c6e168066217, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Dec 31 07:30:13 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381240, encodeId=048138124057, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=090d49833, createdName=LaserDermatol, createdTime=Thu Apr 02 01:04:25 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559002, encodeId=7c62155900241, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Apr 01 04:30:13 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565011, encodeId=927e15650115c, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Apr 01 04:30:13 CST 2020, time=2020-04-01, status=1, ipAttribution=)]
    2020-12-31 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=2079008, encodeId=c59020e9008f9, content=<a href='/topic/show?id=6035e44096e' target=_blank style='color:#2F92EE;'>#神经皮肤黑变病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74409, encryptionId=6035e44096e, topicName=神经皮肤黑变病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Fri Apr 24 06:30:13 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680662, encodeId=8c6e168066217, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Dec 31 07:30:13 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381240, encodeId=048138124057, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=090d49833, createdName=LaserDermatol, createdTime=Thu Apr 02 01:04:25 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559002, encodeId=7c62155900241, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Apr 01 04:30:13 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565011, encodeId=927e15650115c, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Apr 01 04:30:13 CST 2020, time=2020-04-01, status=1, ipAttribution=)]
    2020-04-02 LaserDermatol

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2079008, encodeId=c59020e9008f9, content=<a href='/topic/show?id=6035e44096e' target=_blank style='color:#2F92EE;'>#神经皮肤黑变病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74409, encryptionId=6035e44096e, topicName=神经皮肤黑变病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Fri Apr 24 06:30:13 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680662, encodeId=8c6e168066217, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Dec 31 07:30:13 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381240, encodeId=048138124057, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=090d49833, createdName=LaserDermatol, createdTime=Thu Apr 02 01:04:25 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559002, encodeId=7c62155900241, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Apr 01 04:30:13 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565011, encodeId=927e15650115c, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Apr 01 04:30:13 CST 2020, time=2020-04-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2079008, encodeId=c59020e9008f9, content=<a href='/topic/show?id=6035e44096e' target=_blank style='color:#2F92EE;'>#神经皮肤黑变病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74409, encryptionId=6035e44096e, topicName=神经皮肤黑变病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Fri Apr 24 06:30:13 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680662, encodeId=8c6e168066217, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Dec 31 07:30:13 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381240, encodeId=048138124057, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=090d49833, createdName=LaserDermatol, createdTime=Thu Apr 02 01:04:25 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559002, encodeId=7c62155900241, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Apr 01 04:30:13 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565011, encodeId=927e15650115c, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Apr 01 04:30:13 CST 2020, time=2020-04-01, status=1, ipAttribution=)]

相关资讯

BMJ:APP用于疑似皮肤癌患者的识别效果研究

研究认为,现阶段APP用于可疑皮肤癌病变的识别能力较差

2019 欧洲多学科共识指南:黑色素瘤的诊断

2020年1月,由欧洲皮肤病学论坛(EDF)、欧洲皮肤肿瘤协会(EADO)和欧洲癌症治疗研究组织(EORTC)组成的多学科专家小组共同发布了黑色素瘤指南之诊断部分,文章主要针对黑色素瘤诊断的相关内容提出指导。

Lancet Oncol:肿瘤突变负荷联合IFNγ基因表达特征可预测靶向治疗的III期黑色素瘤患者的预后

在COMBI-AD 3期试验中,达拉菲尼联合曲米替尼辅助治疗降低了BRAFv600突变的III期黑色素瘤患者手术切除后的复发风险。本前瞻性生物标志物探索性分析旨在评估潜在的预后或预测因素和对辅助靶向治疗的耐药机制。COMBI-AD试验是一项随机的双盲的安慰剂为对照的3期试验,对比达拉菲尼(150mg,2/日,口服)联合曲米替尼(2mg,2/日,口服 )与安慰剂。受试患者为年满18岁的进行手术完全切

2020年ASCO-SITC:针对高危黑色素瘤患者的个体化疫苗取得喜人结果

生物药物公司Elios目前正在开发个体化癌症疫苗,该公司今日宣布,前瞻性、随机、双盲、安慰剂对照的IIb期临床试验取得喜人结果,该试验旨在评估负载颗粒的树突状细胞(TLPLDC)疫苗治疗III和IV期黑色素瘤患者的有效性和安全性。

2019 欧洲多学科共识指南:黑色素瘤的治疗(更新版)

2019年12月,由欧洲皮肤病学论坛(EDF)、欧洲皮肤肿瘤协会(EADO)和欧洲癌症治疗研究组织(EORTC)组成的多学科专家小组共同发布了黑色素瘤的治疗指南,主要内容涉及皮肤黑色素瘤的诊断和管理。

2020年ASCO-SITC:抗生素会降低黑色素瘤患者经免疫检查点抑制剂治疗的有效性

根据2020年美国临床肿瘤学会(ASCO)的一项研究,在开始使用免疫检查点抑制剂治疗后3个月内,广谱抗生素暴露与III期和IV期黑色素瘤患者的总生存期(OS)降低显著相关。

拓展阅读

European Radiology:黑色素瘤治疗新警示,BRAFi/MEKi 疗法或显著增加肠系膜脂膜炎风险

BRAF/MEK 抑制剂(BRAFi/MEKi)以及 PD-1 和 CTLA-4 免疫检查点抑制剂(ICI)彻底改变了恶性黑色素瘤的治疗方式,并显著改善了患者的临床预后。

大咖谈 | 黑色素瘤的围手术期治疗

本文回顾了2024年辅助治疗及新辅助的治疗的研究进展,从靶向及免疫治疗多方面分析了黑色素瘤围手术治疗的选择。

2025 CSCO 指南会 | 从免疫治疗到mRNA疫苗:陈誉教授解读黑色素瘤前沿技术与挑战

在2025 CSCO指南会上,【医悦汇】特邀福建省肿瘤医院陈誉教授做客对话大咖深入探讨中国黑色素瘤的发病特点、病理类型差异以及新兴治疗技术的研究进展。

Cancer Cell:皮肤脂肪细胞脂质决定黑色素瘤转移 “去向”

该研究揭示了皮肤脂肪细胞分泌的脂质种类对黑色素瘤转移和器官趋向性的重要影响。这一发现不仅为理解黑色素瘤转移的机制提供了新的视角,还为开发针对黑色素瘤转移的治疗策略提供了潜在的靶点。

中山大学巢晖团队最新《JACS》:突破乏氧限制!新型压电声敏剂克服黑色素瘤免疫治疗瓶颈

中山大学巢晖团队构建 Ir-C3N5 纳米配合物作压电声敏剂,在超声下产 ROS,诱导细胞自噬抑制与焦亡,激活免疫,有效抑制黑色素瘤生长转移。

2025 CSCO 指南会 | 连斌教授解读CSCO黑色素瘤诊疗指南更新:从国际接轨到中国创新

在CSCO指南会上,【医悦汇】对话大咖栏目特邀北京大学肿瘤医院连斌教授深入探讨了中国黑色素瘤诊疗规范的特色、最新指南的更新内容,以及多学科协作治疗(MDT)模式的重要性。